Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
This study is ongoing, but not recruiting participants.
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00750893
First received: September 10, 2008
Last updated: June 28, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This protocol posting deals with objectives and outcome measures of the primary phase at one month post-Dose 2. This Post Marketing Surveillance (PMS) will collect safety data on the use of human rotavirus vaccine in at least 3000 evaluable infants in Korea. This study involves male or female infants from the age of 6 weeks at the time of the first vaccination. The vaccination course must be completed by the age of 24 weeks.
| Condition | Intervention |
|---|---|
|
Rotavirus Gastroenteritis |
Other: Data Collection |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ or Rotarix™ Liquid Formulation (Oral Suspension or Prefilled Syringe) When Administered According to the Prescribing Information in Korea |
Resource links provided by NLM:
MedlinePlus related topics:
Gastroenteritis
Drug Information available for:
Rotarix
U.S. FDA Resources
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Number of Subjects Reporting Solicited General Symptoms [ Time Frame: During the 8 day follow-up period after each vaccine dose for Year 1 & Year 2 study period ] [ Designated as safety issue: No ]Solicited general symptoms assessed include cough, diarrhoea, irritability, loss of appetite, temperature and vomiting.
- Number of Subjects Reporting Unsolicited Adverse Events (AEs) [ Time Frame: During the 31 day follow-up period after each vaccine dose for Year 1 & Year 2 study period ] [ Designated as safety issue: No ]Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
- Number of Subjects Reporting Unsolicited Adverse Events (AEs) [ Time Frame: During the 31 day follow-up period after each vaccine dose for Year 3 & Year 4 study period ] [ Designated as safety issue: No ]Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
- Number of Subjects Reporting Unsolicited Adverse Events (AEs) [ Time Frame: During the 31 day follow-up period after each vaccine dose for Year 5 & Year 6 study period ] [ Designated as safety issue: No ]Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
- Number of Subjects Reporting Serious Adverse Events (SAEs) [ Time Frame: During the post marketing study period for Year 1 & Year 2 study period ] [ Designated as safety issue: No ]SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
- Number of Subjects Reporting Serious Adverse Events (SAEs) [ Time Frame: During the post marketing study period for Year 3 & Year 4 study period ] [ Designated as safety issue: No ]SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
- Number of Subjects Reporting Serious Adverse Events (SAEs) [ Time Frame: During the post marketing study period for Year 5 & Year 6 study period ] [ Designated as safety issue: No ]SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
| Enrollment: | 1052 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | December 2013 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Rotarix Group
Subjects who received 2 doses of Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe ). The first dose was administered from the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
|
Other: Data Collection
Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
|
Detailed Description:
The protocol posting has been amended to reflect the two new vaccine presentations that have been launched in Korea. The current PMS will thus collect safety information from subjects who have received either Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe) in the course of their routine clinical practice according to the prescribing information in Korea.
Eligibility| Ages Eligible for Study: | 6 Weeks to 24 Weeks |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Infants aged at least 6 weeks will be administered two doses of Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe) orally as per the prescribing information in Korea.
Criteria
Inclusion Criteria:
- Infants who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the PMS.
- A male or female infant from the age of 6 weeks at the time of the first vaccination.
- Written informed consent obtained from the parent or guardian of the infant.
Exclusion Criteria:
• At the time of PMS entry, the contraindications and precautions of use indicated in the prescribing information should be checked and the infant must not be included in the PMS if there is any contraindication. Any changes in the locally approved Prescribing Information must be implemented immediately.
Contacts and Locations More Information
No publications provided
| Responsible Party: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00750893 History of Changes |
| Other Study ID Numbers: | 111700 |
| Study First Received: | September 10, 2008 |
| Results First Received: | January 28, 2011 |
| Last Updated: | June 28, 2012 |
| Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
Keywords provided by GlaxoSmithKline:
|
Gastroenteritis |
Additional relevant MeSH terms:
|
Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013